2016 International Congress Archives - Page 26 of 207

12:00pm-1:30pm: Highlighting the spectrum of practice in the routine management of cervical dystonia with botulinum neurotoxin-A: Baseline injection practice data from MetaCD

R. Trosch, V.P. Misra, S. Om, P. Maisonobe (Farmington Hills, MI, USA)

Dystonia · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature

R.W.K. Borgemeester, G.F.H. Diercks, M.L.A. Schuttelaar, T. van Laar (Groningen, Netherlands)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Home care program for patients with Parkinson’s disease – A Singapore experience

H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: How accurate is the prediction of driving ability in a Parkinson’s clinic setting?

C. Thomas, R. Amin, B. Mohamed (Cardiff, United Kingdom)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: How satisfied are cervical dystonia patients with their botulinum toxin treatment? Findings from an international observational study

V.P. Misra, C. Colosimo, D. Charles, T.M. Chung, P. Maisonobe, S. Om (London, United Kingdom)

Dystonia and Pediatric Movement Disorders

12:00pm-1:30pm: Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

Neuropharmacology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Impaired processing of visuo-spatial information in cervical dystonia patients

C.J. Amlang, C. Hubsch-Bonneaud, S. Rivaud-Pechoux, S. Mehdi, A. El Helou, Y. Trotter, J.B. Durand, P. Pouget, M. Vidailhet (Berlin, Germany)

Dystonia · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Impaired response times to luminance stimuli in dystonia patients indicate disordered superior colliculus processing

L. Williams, J.S. Butler, B. Quinlivan, A. Molloy, E. McGovern, I. Beiser, M. Thirkettle, S. O'Riordan, P. Redgrave, R. Reilly, M. Hutchinson (Dublin, Ireland)

Dystonia · Exhibit Hall located in Hall B, Level 2